Washington University School of Medicine in St. Louis | Strategic Alliance Partners

February 13, 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

February 07, 2019

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

January 23, 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

December 20, 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

November 29, 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).

November 27, 2018

Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.

November 21, 2018

Geoffrey Uy, MD, discusses the impact of targeted therapies on the treatment of patients with newly diagnosed acute myeloid leukemia.

November 20, 2018

Ravi Vij, MD, discusses emerging treatment options for patients with newly diagnosed multiple myeloma.

November 10, 2018

Meagan A. Jacoby, MD, PhD, discusses treatment-free remissions in patients with chronic-phase chronic myeloid leukemia.

November 03, 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the potential of quadruplets in the treatment of patients with multiple myeloma.

October 25, 2018

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

September 19, 2018

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer despite its challenges.

September 06, 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the construction of antibody-drug conjugates for the treatment of patients with lymphoma.

February 23, 2018

Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.

February 20, 2018

David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.

May 11, 2017

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

May 11, 2017

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non–small cell lung cancer (NSCLC).

May 11, 2017

Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).

May 06, 2017

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in non-small cell lung cancer and what researchers are poised to do next in the field.

February 23, 2016

Researchers at Washington University in St. Louis and elsewhere are focusing on lymphocytes, the essential effector cells in the immune response to cancer.